The TAK1/ROS pathway: a mediator of adhesive signaling?

TAK1/ROS 通路:粘附信号传导的介质?

基本信息

  • 批准号:
    RGPIN-2016-04756
  • 负责人:
  • 金额:
    $ 2.4万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Discovery Grants Program - Individual
  • 财政年份:
    2016
  • 资助国家:
    加拿大
  • 起止时间:
    2016-01-01 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

Tissue architecture is maintained by the underlying connective tissue. In skin, the structure and organization of connective tissue provides support for surface epithelia and generates the skin’s elasticity and barrier functions. Connective tissue is comprised largely of extracellular matrix (ECM, which includes collagen). Within connective tissue, fibroblasts, which are responsible for producing and remodeling the ECM and hence for connective tissue function. In response to injury, a form of differentiated fibroblast, the myofibroblast (so called as it expresses the highly contractile protein alpha-smooth muscle actin), is responsible for producing and remodeling new ECM; myofibroblasts disappear during normal repair but, in scarred (fibrotic) tissue abnormally. Understanding how fibroblasts contribute to dermal homeostasis and repair is essential not only for understanding fibroblast function and skin homeostasis but also how to properly engineer replacement skin tissue which should integrate within the normal tissue without contractions (i.e., without scarring). The cytokine transforming growth factor (TGF) beta potently induces fibroblasts to produce and remodel ECM via both canonical pathway and non-canonical pathways, the latter of which involves adhesive signaling operating through integrin beta1 and focal adhesion kinase (FAK). Loss of integrin beta1 by fibroblasts results in impaired myofibroblast formation and delayed tissue repair kinetics. Moreover, expression of the phosphatase PTEN (Phosphatase and tensin homolog), which inactivates adhesive signaling by dephosphorylating FAK, is decreased in activated dermal fibroblasts; loss of PTEN expression by dermal fibroblasts significantly increased dermal thickness in vivo and elevated ECM production and contractile responses by fibroblasts both in vivo and in vitro. TGFbeta activated kinase (TAK)1 pathway operates downstream of FAK to promote ECM remodeling in response to TGFbeta. TAK1 expression by fibroblasts is required for maintaining normal skin thickness and for the induction of myofibroblasts in response to tissue injury. This non-canonical TGF beta pathway appears to specifically control contractile responses to TGF beta. However, the fundamental signaling mechanisms through which adhesion/TAK1 mediates the ability of fibroblasts to produce and remodel ECM are unclear. We also showed that fibroblasts actively undergoing ECM production/remodeling have integrin beta 1-mediated ROS generation was required for the expression of genes involved with ECM production and remodeling. Collectively, these data suggest the intriguing idea that the ability of fibroblasts to actively engage in ECM remodeling in response to factors such as TGF beta occurs via an adhesive signaling/TAK/ROS-dependent mechanism. However, this hypothesis has not been evaluated, and is the subject of this proposal.
组织结构由下层结缔组织维持。在皮肤中,结缔组织的结构和组织为表面上皮细胞提供支持,并产生皮肤的弹性和屏障功能。结缔组织主要由细胞外基质(ECM,其包括胶原)组成。在结缔组织内,成纤维细胞负责产生和重塑ECM,因此负责结缔组织功能。响应于损伤,分化的成纤维细胞的一种形式,肌成纤维细胞(所谓肌成纤维细胞是因为其表达高度收缩性蛋白α-平滑肌肌动蛋白)负责产生和重塑新的ECM;肌成纤维细胞在正常修复期间消失,但在瘢痕(纤维化)组织中异常消失。理解成纤维细胞如何促进真皮稳态和修复不仅对于理解成纤维细胞功能和皮肤稳态是必不可少的,而且对于如何正确地工程化替代皮肤组织也是必不可少的,所述替代皮肤组织应该在没有收缩的情况下整合在正常组织内(即,没有疤痕)。细胞因子转化生长因子(TGF)β通过经典途径和非经典途径有效诱导成纤维细胞产生和重塑ECM,后者涉及通过整合素β 1和粘着斑激酶(FAK)操作的粘附信号传导。成纤维细胞缺失整合素β 1导致肌成纤维细胞形成受损和组织修复动力学延迟。此外,磷酸酶PTEN(磷酸酶和张力蛋白同源物)的表达(其通过使FAK去磷酸化来灭活粘附信号传导)在活化的真皮成纤维细胞中降低;真皮成纤维细胞的PTEN表达的丧失显著增加了体内真皮厚度,并提高了体内和体外成纤维细胞的ECM产生和收缩反应。TGF β激活激酶(TAK)1通路在FAK下游起作用,促进ECM对TGF β的重塑。成纤维细胞的TAK 1表达是维持正常皮肤厚度和诱导肌成纤维细胞响应组织损伤所必需的。这种非经典的TGF β途径似乎特异性地控制对TGF β的收缩反应。然而,粘附/TAK 1介导成纤维细胞产生和重塑ECM的能力的基本信号传导机制尚不清楚。我们还表明,成纤维细胞积极进行ECM生产/重塑整合素β 1介导的活性氧的产生所需的基因表达与ECM的生产和重塑。总的来说,这些数据表明了一个有趣的想法,即成纤维细胞通过粘附信号传导/TAK/ROS依赖性机制主动参与ECM重塑以响应TGF β等因子的能力。然而,这一假设尚未得到评估,这是本提案的主题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leask, Andrew其他文献

Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis
  • DOI:
    10.2302/kjm.53.74
  • 发表时间:
    2004-06-01
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Leask, Andrew
  • 通讯作者:
    Leask, Andrew
CCN2 Is Required for Bleomycin-Induced Skin Fibrosis in Mice
  • DOI:
    10.1002/art.30074
  • 发表时间:
    2011-01-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Liu, Shangxi;Xu Shi-wen;Leask, Andrew
  • 通讯作者:
    Leask, Andrew
Fibrosis Caused by Loss of PTEN Expression in Mouse Fibroblasts Is Crucially Dependent on CCN2
  • DOI:
    10.1002/art.38121
  • 发表时间:
    2013-11-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Liu, Shangxi;Parapuram, Sunil K.;Leask, Andrew
  • 通讯作者:
    Leask, Andrew
A tale of two orgins: do myofibroblasts originate from different sources in wound healing and fibrosis?
  • DOI:
    10.1007/s00441-016-2419-5
  • 发表时间:
    2016-09-01
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Hutchenreuther, James;Leask, Andrew
  • 通讯作者:
    Leask, Andrew
Loss of protein kinase Cε results in impaired cutaneous wound closure and myofibroblast function
  • DOI:
    10.1242/jcs.029215
  • 发表时间:
    2008-10-15
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Leask, Andrew;Shi-Wen, Xu;Abraham, David J.
  • 通讯作者:
    Abraham, David J.

Leask, Andrew的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leask, Andrew', 18)}}的其他基金

The TAK1/ROS pathway: a mediator of adhesive signaling?
TAK1/ROS 通路:粘附信号传导的介质?
  • 批准号:
    RGPIN-2016-04756
  • 财政年份:
    2021
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Discovery Grants Program - Individual
The TAK1/ROS pathway: a mediator of adhesive signaling?
TAK1/ROS 通路:粘附信号传导的介质?
  • 批准号:
    RGPIN-2016-04756
  • 财政年份:
    2019
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Discovery Grants Program - Individual
The TAK1/ROS pathway: a mediator of adhesive signaling?
TAK1/ROS 通路:粘附信号传导的介质?
  • 批准号:
    RGPIN-2016-04756
  • 财政年份:
    2018
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Discovery Grants Program - Individual
The TAK1/ROS pathway: a mediator of adhesive signaling?
TAK1/ROS 通路:粘附信号传导的介质?
  • 批准号:
    RGPIN-2016-04756
  • 财政年份:
    2017
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Discovery Grants Program - Individual
CCN3: a novel antifibrotic treatment?
CCN3:一种新型抗纤维化治疗?
  • 批准号:
    493636-2016
  • 财政年份:
    2017
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Collaborative Health Research Projects
CCN3: a novel antifibrotic treatment?
CCN3:一种新型抗纤维化治疗?
  • 批准号:
    493636-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Collaborative Health Research Projects

相似国自然基金

LncRNA PURPL激活ROS通路促进皮肤成纤维细胞衰老的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
牙龈卟啉单胞菌通过ROS/FOXO1/GSDMD轴诱导巨噬细胞焦亡的机制研究
  • 批准号:
    JCZRQN202500447
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
扶正康复合剂通过调控ROS-CP/FPN轴维持铁-铜离子代谢稳态缓解心肌梗死的机制研究
  • 批准号:
    KLY25H270026
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
(PFTBA/BMSC)TPA@SFN-LP通过持续供氧及ROS清除促进糖尿病创面修复及毛囊再生
  • 批准号:
    KLY25H180097
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
ROS-FoxO介导细胞自噬调控刺参肠道再生的分子机制研究
  • 批准号:
    QN25C190009
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
pH,ROS顺序响应载药纳米胶束抑制膝骨关节炎机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
TXNIP 通过上调细胞内ROS水平促进DNA损伤抑制鼻咽癌细胞的放疗抵抗
  • 批准号:
    2025JJ70551
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
“搭便车”中性粒细胞的ROS响应型多功能基因递送系统的构建及IS后的协同神经保护研究
  • 批准号:
    2025JJ60794
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于ROS响应-靶向巨噬细胞的超分子纳米药物载体的构建及其抗炎机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目

相似海外基金

ROS Signaling in Wound Healing vs Tissue Repair
伤口愈合与组织修复中的 ROS 信号传导
  • 批准号:
    10654242
  • 财政年份:
    2023
  • 资助金额:
    $ 2.4万
  • 项目类别:
The role of NQR in ROS-dependent virulence regulation in Vibrio cholerae
NQR 在霍乱弧菌 ROS 依赖性毒力调节中的作用
  • 批准号:
    10721326
  • 财政年份:
    2023
  • 资助金额:
    $ 2.4万
  • 项目类别:
Mitochondrial complex III-derived ROS in astrocytic signaling and Alzheimer's disease-related pathogenesis
线粒体复合物 III 衍生的 ROS 在星形胶质细胞信号传导和阿尔茨海默病相关发病机制中的作用
  • 批准号:
    10749159
  • 财政年份:
    2023
  • 资助金额:
    $ 2.4万
  • 项目类别:
ROS scavenging nanoparticles for mitigating oxidative stress in osteoarthritis
ROS清除纳米颗粒可减轻骨关节炎的氧化应激
  • 批准号:
    10584738
  • 财政年份:
    2023
  • 资助金额:
    $ 2.4万
  • 项目类别:
Role of epithelial ROS signaling in mediating psychological stress-induced mucosal dysfunction and colitis predisposition
上皮ROS信号在介导心理应激引起的粘膜功能障碍和结肠炎易感性中的作用
  • 批准号:
    10667614
  • 财政年份:
    2022
  • 资助金额:
    $ 2.4万
  • 项目类别:
Role of epithelial ROS signaling in mediating psychological stress-induced mucosal dysfunction and colitis predisposition
上皮ROS信号在介导心理应激引起的粘膜功能障碍和结肠炎易感性中的作用
  • 批准号:
    10521707
  • 财政年份:
    2022
  • 资助金额:
    $ 2.4万
  • 项目类别:
Characterizing the impacts of a novel environmental contributor on ROS hormesis and aging in C. elegans
表征新型环境贡献者对线虫 ROS 兴奋作用和衰老的影响
  • 批准号:
    10287981
  • 财政年份:
    2021
  • 资助金额:
    $ 2.4万
  • 项目类别:
Modulating ROS by Electromagnetic Fields to Treat Type 2 Diabetes
通过电磁场调节 ROS 治疗 2 型糖尿病
  • 批准号:
    10570226
  • 财政年份:
    2021
  • 资助金额:
    $ 2.4万
  • 项目类别:
The TAK1/ROS pathway: a mediator of adhesive signaling?
TAK1/ROS 通路:粘附信号传导的介质?
  • 批准号:
    RGPIN-2016-04756
  • 财政年份:
    2021
  • 资助金额:
    $ 2.4万
  • 项目类别:
    Discovery Grants Program - Individual
Modulating ROS by Electromagnetic Fields to Treat Type 2 Diabetes
通过电磁场调节 ROS 治疗 2 型糖尿病
  • 批准号:
    10393667
  • 财政年份:
    2021
  • 资助金额:
    $ 2.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了